Contract Option Exercises — March 14, 2026

Five VA awards totaling $1.65B (33% of period value) to TriWest, Veterans Evaluation, Cognosante, Technatomy, Richard Group via full/open competition signal robust demand for medical/IT services.

Four HHS awards worth $1.1B to Advanced Tech Int, MAPP Bio, ThirdPacket for R&D/IT underscore BARDA/CMS funding stability through 2029+.

L3Harris ($814M NASA to 2029), Lockheed ($65M DHS to 2026), Boeing sub Insitu ($96M DHS to 2026) provide long-term revenue in space/C4ISR.

Firm fixed price prevalent (9/15 contracts) exposes winners like TriWest, BL Harbert to cost overruns; long periods (avg ~5yrs) in 11/15 amplify delays/obsolescence.

Low/zero outlays in 8/15 ($2.1B value) including TriWest ($820M, $0 outlaid), BL Harbert ($814M, $0) signal delayed cash flows amid future starts (e.g., 2026).

Heavy subawards (e.g., L3Harris $169M/538 subs, Salient $187M/128) create subcontractor dependencies; non-competed awards (3/15) like BL Harbert limit rivalry but risk sole-source scrutiny.

$2B+ in unobligated options (e.g., Salient $454M, MAPP $722M, Cognosante $241M) offer expansion if exercised.

Set-aside advantages for vet/SDVOSB/8(a) winners (Technatomy, Richard Group, ThirdPacket, ITSI; $352M total) position for repeat VA/HHS/DHS work.

Short-duration high-value like TriWest $820M (1-mo Feb 2026) could seed follow-on VA insurance deals post-execution.

VA/HHS dominate with $2.8B (56%) across medical eval, DevSecOps, biotech R&D; full competition wins to non-profits/small biz signal sustained outlays.

Aerospace/engineering awards (L3Harris, Lockheed, Insitu) total $973M through 2029+ with cost-plus flexibility.

{"entity"=>"TriWest Healthcare", "reason"=>"$820M VA award is largest/single-month outlier; $0 outlay/execution post-Feb 2026 critical for follow-ons.", "trigger"=>"outlays >10% by Q2 2026 or missed performance"}

{"entity"=>"L3Harris Technologies", "reason"=>"$814M NASA to 2029 with $216M outlaid anchors space revenue; $19M options upside.", "trigger"=>"subaward delays or tech milestone slips"}

{"entity"=>"MAPP Biopharmaceutical", "reason"=>"Small biz with $185M obligated/$906M ceiling in viral therapeutics; BARDA options key to scaling.", "trigger"=>"option exercise announcements"}

{"entity"=>"VA IT Contractors (Cognosante, Technatomy)", "reason"=>"$377M combined with $234M outlaid/options; DevSecOps trend for multi-year growth.", "trigger"=>"extension to potential ends (2026-2029)"}